Amira Al Balakosy

Dr. Amira Al Balakosy

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2020 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AMAmal Tohamy Abdel Moez
Amal Tohamy Abdel Moez
YHYomna Ahmed El Hawary
Yomna Ahmed El Hawary
ABAmira Al Balakosy
Amira Al Balakosy
Background: Depression is the most common extrahepatic neuropsychiatric manifestation in chronic hepatitis C (CHCV) and is due to direct neuropathogenic mechanisms. Our aim is to evaluate the effect of viral clearance by directly acting antivirals (DAAs) on depression in CHCV patients. Methods: One hundred fifty chronic HCV patients eligible for DAAs were assessed for depression using the Beck depression inventory (BDI) scale at baseline, 1 and 3 months after end of treatment (EOT). BDI ≥10 reliable in detecting depression in CHCV. Results: All included patients received Sofosbuvir/Dacltasvir ± Ribavirin for 12 weeks and all achieved sustained virological response (SVR). Baseline BDI of all included patients was 10 ± 5 then decreased to 5.3 ± 5 and 3.5 ± 4.5 at 1 and 3 months after EOT (P = 0.001), respectively. After EOT, 20 patients (13.3%) had BDI >10 which were 11.35 ± 6.5 and 13.3 ± 3.2 at 1 and 3 months (SVR), respectively. A comparison between patients with high and low BDI after EOT showed that patients with persistent high score were older (60.6 ± 9.5vs 52.2 ± 10.6, P = 0.001) and included higher percentage of females (50% vs 22.3%, P = 0.01). Also high BDI patients had higher baseline FIB4 (3 ± 1.6 vs 2 ± 1.3, P = 0.006) and included more patients with significant fibrosis (40% vs 17.7%, P = 0.05), as well as lower baseline hemoglobin (13.6 ± 1.5 vs 14.4 ± 1.65, P = 0.04). Conclusion: Depression associated with CHCV improves after successful treatment with DAAs; however, it may persist in elderly females with significant fibrosis and low hemoglobin.

28 May 2025 in Egyptian Liver Journal
Verified
Journal Article
Open access
PDF file
ABAmira Al Balakosy
Amira Al Balakosy
MMMarwa Ahmed Mohamed
Marwa Ahmed Mohamed
AHAzza Mohammed Hassan
Azza Mohammed Hassan
EBEthar Mokhtar Badran
Ethar Mokhtar Badran
Background and Aim: Health-related quality of life (HRQoL) is a multidimensional concept encompassing the physical, psychological, and social aspects of health. Although inactive hepatitis B virus (HBV) carriers appear healthy, they live with lifelong chronic infections that may present various challenges in their daily lives. Understanding these impacts enables clinicians to address the broader consequences of the disease on patients' well-being. Objectives: This study aims to assess the HRQoL of HBV carriers compared to healthy controls using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) scale and identify the most affected domains among HBV carriers. Patients and Methods: This case–control study enrolled chronic HBV patients attending the Viral Hepatitis Outpatient Clinic (OPC) at Ain Shams University. Patients were included if they met the criteria for chronic carrier status, had undetectable or low HBV DNA levels (< 2,000 IU/mL), and exhibited normal alanine aminotransferase (ALT) levels (ULN < 40 IU/L). Healthy controls with no history of chronic illness were also included. To assess HRQoL, the Arabic version of the World Health Organization Quality of Life Assessment Instrument, Short Version (WHOQOL-BREF), was used. Scores were analyzed and compared between the two groups. Results: A total of 60 patients with chronic HBV infection, confirmed to be in the carrier state by low viremia were included in the study. Among them, HBV quantitative PCR was negative in 10 carriers (16.7%) and positive in 50 carriers, with a mean viral load of 431 ± 512 IU/mL. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) levels were within the normal range (20 ± 7 IU/mL and 20 ± 9 IU/mL, respectively). The majority of participants were female (62%), with a mean age of 41 ± 9 years. Additionally, 55% had at least a primary level of education, most were married (90%), and 36.7% were housewives. The total HRQoL score in HBV carriers (77 ± 19) was significantly lower than that of healthy controls (86 ± 12) (p = 0.001). Among HBV carriers, scores in the physical (23.5 ± 7), psychological (19 ± 4.6), and environmental (22.5 ± 6.3) domains were significantly lower compared to controls (29 ± 4, 21 ± 3, and 26 ± 6, respectively) (p < 0.001, p = 0.001, and p = 0.004, respectively), with the greatest difference observed in the physical domain. Factors such as age, comorbidities, and laboratory findings did not significantly impact overall QoL scores. Conclusion: HBV carriers experience impaired quality of life, with physical functioning being the most significantly affected domain. These findings highlight the need for holistic care strategies for HBV carriers.

1 July 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MEMohamed El-Kassas
Mohamed El-Kassas
MAMohamed Alboraie
Mohamed Alboraie
MBMohamed El Badry
Mohamed El Badry
NYNaglaa Youssef
Naglaa Youssef
HOHeba Omar
Heba Omar
WDWahid Doss
Wahid Doss
The current study aimed to evaluate the efficacy of different DAAs regimens in the treatment of chronic hepatitis C (CHC) Egyptian patients who failed to achieve SVR after their treatment with SOF-based regimens. This was a retrospective observational multicenter study that included CHC patients that failed to achieve cure on SOF-based regimens who were re-treated using different DAAs regimen and were allocated according to national guidelines for the treatment of hepatitis C. Primary outcome was to assess the SVR12 rate among prior non-responders after retreatment with a second course of DAAs. Our study included 172 patients who failed to achieve SVR after treatment with SOF-based treatment regimen [ age: 51.2 ± 11.3, 58.7% men]. Included patients were retreated using SOF/DCV/RBV, SOF/ r/PAR /OMB /RBV, SOF/DCV/SIM, SOF/LDV ± RBV or SIM/SOF. SVR12 was successfully attained in 95.35% (164/172) of the included non-responders. The current multicenter study proved the efficacy of various DAAs regimens issued by the National Committee for Control of Viral Hepatitis for retreatment of relapsed CHC Egyptian patients.

16 April 2024 in The Egyptian Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
ABAmira Al Balakosy
Amira Al Balakosy
SASaffaa Askar
Saffaa Askar
RNRehab Mohamed Naguib
Rehab Mohamed Naguib
SASherif Ayman
Sherif Ayman
HMHend Mubarak
Hend Mubarak
Background: Ulcerative colitis (UC) and Crohn’s disease (CD) imply chronic intestinal inflammation with both local and systemic manifestations. Cognition is a lifelong process of learning and memory processing, which has been identified to be affected by chronic systemic illnesses. Aim: To evaluate the cognitive functions in inflammatory bowel disease (IBD) patients in remission Patients and methods: Inclusion criteria are as follows: 70 IBD patients in remission and a group of 50 healthy control. Mini-mental state examination (MMSE) was used for assessment of global cognitive function and Trail Making Test (TMT) for assessment of executive functions. TMT consists of part A which measures attention and performance speed and part B which measures mental flexibility. Both tests have been previously validated on Arabic-speaking populations. Results: The study included 70 patients (50 UC and 20 CD), who have been in remission for 21 ± 9 months. Of the included cases, about 51 were already on steroids ± azathioprine, and 19 patients were on biologics. Males represented 60% (n = 42) while females 40% (n = 28), and their mean age was 34 ± 8 years. Both cases and controls were matched for age and sex. The mean score of MMSE among IBD cases was significantly worse than controls (28.5 ± 3 versus 30, P < 0.001). Also, the duration of TMT parts A and B was significantly longer in cases than controls. The cases group scored 32 ± 19.5 s in TMT part A, versus 23 s by the controls. In TMT B, the recorded scores were 255 ± 48, versus 234 s in cases and control groups respectively (P < 0.001). In the cases group, 6 patients (8%) had below normal MMSE score of less than 24, with mild (3 patients, mean score was 21) to moderate cognitive impairment (3 patients, mean score was 15). The presence of extraintestinal manifestation was the only disease-related factor that was associated with cognitive impairment. Of the patient-related factor: older age, being divorced, and living in rural areas were associated with poorer cognitive functions. Conclusion: IBD patients potentially suffer from cognitive impairment. In our study, factors as extraintestinal complications, older age, marital status, and residence in rural areas could be contributing factors to this impairment.

28 August 2021 in Egyptian Liver Journal
Verified
Journal Article
Open access
PDF file
NANadia Abdel Ataay Abdelkader
Nadia Abdel Ataay Abdelkader
OAOsama Ashraf Ahmed
Osama Ashraf Ahmed
ASAhmed Fouad Sherief
Ahmed Fouad Sherief
DKDoaa Mahmoud Kandil
Doaa Mahmoud Kandil
MGMohammed Soliman Gado
Mohammed Soliman Gado
ABAmira Al Balakosy
Amira Al Balakosy
Background: A large number of chronic hepatitis C patients had been successfully treated by directly acting antivirals; therefore, strategies for the long-term follow-up of these patients have to be planned based on the post-treatment fibrosis stage—the main determinant of prognosis. In this study, we aim to evaluate changes in aspartate-platelet ratio index, FIB4, and liver stiffness in chronic hepatitis C patients who achieved SVR and ended treatment more than 1 year by DAAs. Results: One hundred chronic hepatitis C patients who achieved SVR were enrolled at a median of 16 months after the end of treatment by DAAs. According to the baseline liver stiffness, 63 and 37 patients belonged to early (F0, F1, and F2) and advanced (F3 and F4) fibrosis stages, respectively. Both groups showed a decline of the degree of liver stiffness at follow-up compared to the baseline that was statistically significant in the early fibrosis group (5.9±1.5 vs 5.4±2.2 Kpcal, p=0.04), while measurements in the advanced group were (18±8.8 vs 15.9 ± 7.8 Kpcal, p=0.07). Also, serum biomarkers of fibrosis improved in both groups, where the recorded APRI and FIB4 before and after treatment were 0.42±0.3 vs 0.24±0.1, p<0.01 and 1±0.6 vs 0.93 ±0.5, p=0.1 in the early group and 0.85 ±0.5 vs 0.4±0.2, p <0.001 and 2.9±2.3 vs 1.8±1.4, p<0.02) in the advanced group, respectively. Changes in APRI and FIB4 correlated with changes in AST and ALT, but liver stiffness changes were not affected by changes in liver enzymes. Conclusion: Although long-term improvement of APRI, FIB4, and liver stiffness scores could be achieved in chronic HCV patients after SVR by DAAS. High measurements of liver stiffness before treatment likely persist. We recommend transient elastography as a reliable tool for fibrosis assessment post-treatment.

25 August 2021 in Afro-Egyptian Journal of Infectious and Endemic Diseases
Verified
Journal Article
Closed access
PDF file
ABAmira Al Balakosy
Amira Al Balakosy
MAMostafa Alfishawy
Mostafa Alfishawy
OEOmnia Elnabawy
Omnia Elnabawy
AHAzza Hassan
Azza Hassan
MSMostafa Abd Alfattah Shamkh
Mostafa Abd Alfattah Shamkh
ASAhmed Sherief
Ahmed Sherief
Background and study aim: Epidemiological data reported lower death rates of COVID-19 cases in countries with higher & ‎recent coverage by measles containing vaccines. In this study we aim to identify measles IgG titer ‎in COVID-19 patients & correlate it with disease severity‎‎‎‎. Patients and Method: ‎This is a Cross-sectional study where 78 patients admitted to Ain Shams University Quarantine ‎hospitals with positive PCR for SARS-CoV-2 were enrolled. All patients underwent ‎quantification of serum measles IgG titer. Then classified according to the COVID-19 severity ‎into mild, moderate and severe‎‎.‎ Results: Measles IgG was positive in 53 patients (68%) with median of 1600 (IQR 1000-or3100), borderline ‎in 18 patients (23%) with median 250 (IQR 200-250) and negative in seven patients (9%) with ‎median 100 (IQR 80-120). Patients with positive measles IgG were significantly older (56±16 ‎years) than those with negative measles IgG ( 48±15 years) (P=0.03).No significant difference ‎was found in measles IgG titer between mild , moderate and severe COVID19 cases. Intensity of ‎pulmonary involvement by CT chest was not correlated with measles IgG titer. The median of ‎measles IgG titer of the ICU admitted patients and those who were not, was 1150 (IQR=600-3500) ‎and 1050 (IQR=200-1800) respectively (p=0.46). No difference in measles IgG titer between ‎patients who recovered or died‎‎‎. Conclusion: Severity of COVID-19 disease and its outcome seem to be unaffected by measles IgG titer‎‎‎‎‎.